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Aims To determine the effect of anti-ischaemic drug therapy on long-term outcomes of asymptomatic
patients without coronary artery disease (CAD) history but silent exercise ST-depression.
Methods and results In a randomizedmulticentre trial, 263 of 522 asymptomatic subjects without CAD but
at least one CAD risk factor in whom silent ischaemia by exercise ECG was conﬁrmed by stress imaging were
asked to participate. The 54 (21%) consenting patients were randomized to anti-anginal drug therapy in
addition to risk factor control (MED, n ¼ 26) or risk factor control-only (RFC, n ¼ 28). They were followed
yearly for 11.2+2.2 years. During 483 patient-years, cardiac death, non-fatal myocardial infarction, or
acute coronary syndrome requiring hospitalization or revascularization occurred in 3 (12%) of MED vs. 17
(61%) of RFC patients (P, 0.001). In addition, MED patients had consistently lower rates of exercise-
induced ischaemia during follow-up, and left ventricular ejection fraction remained unchanged (20.7%,
P ¼ 0.597) in contrast to RFC patients in whom it decreased over time (26.0%, P ¼ 0.006).
Conclusion Anti-ischaemic drug therapy and aspirin seem to reduce cardiac events in subjects with
asymptomatic ischaemia type I. In such patients, exercise-induced ST-segment depression should be
veriﬁed by stress imaging; if silent ischaemia is documented, anti-ischaemic drug therapy and aspirin
should be considered.
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Introduction
Although there is still controversy regarding why ischaemic
episodes are symptomatic in some patients and completely
asymptomatic in others, it is now widely accepted that
silent ischaemia, similar to symptomatic episodes, nega-
tively affects prognosis.1–3 Silent ischaemia may occur in
totally asymptomatic patients without (type I) or with
(type II) a history of an ischaemic cardiac event and coexists
with symptomatic episodes in many patients (type III).1–3 In
the absence of coronary angiography, most investigations on
silent ischaemia relied upon documentation of asympto-
matic ST-segment depression on Holter-ECG recordings or
during stress testing for diagnostic purposes. However,
both test methods have a low sensitivity and a rather high
prevalence of false-positive results in clinically healthy
men.4,5 Accordingly, stress echocardiography (stress
ECHO), myocardial perfusion scintigraphy (MPS), and
radionuclide ventriculography have been used to investigate
the relationship between asymptomatic ST-segment changes
and myocardial ischaemia.6–8
The prognostic impact of silent ischaemia has been
studied in type II and III patients, i.e. in patients with
angina pectoris9 or following myocardial infarction (MI)10,11
as well as in patients after coronary artery bypass graft
surgery12 or angioplasty.13 In addition, the prospective
Asymptomatic Cardiac Ischemia Pilot study and the Atenolol
Silent Ischemia Study have shown beneﬁt of revasculariza-
tion14 or drug therapy14,15 in patients who had silent ischae-
mic episodes in addition to symptomatic ones. However,
there is a lack of data on the prognostic importance of
silent ischaemia in totally asymptomatic subjects without
history of coronary artery disease (CAD), i.e. silent ischae-
mia type I, and, particularly, on a possible beneﬁt of
medical therapy in such patients. Reasons lie in the difﬁculty
to identify such patients and their expected low event rates
implying that large patient populations and/or long
follow-up periods would be necessary to come to deﬁnite* Corresponding author. Tel: þ41 265 52 14; fax: þ41 265 45 98.
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conclusions. Thus, speciﬁc aims of the Swiss Interventional
Study on Silent Ischaemia type I (SWISSI I) were to perform
a pilot feasibility study in totally asymptomatic subjects
older than 40 years of age without any history of CAD but
one cardiovascular risk factor and documented silent ischae-
mia in order to (i) assess the incidence of silent myocardial
ischaemia by an imaging technique, (ii) determine their
long-term prognosis, and (iii) assess the impact of anti-
ischaemic drug therapy and aspirin plus risk factor control
vs. risk factor control-only on outcome.
Participants and methods
Participants
Study participants were recruited from subjects sent for
exercise testing to four Swiss medical centres (Lucerne,
Chur, Zurich, and Basel) between 1992 and 1996. Subjects
with asymptomatic ST-segment depression during bicycle
ergometry and with at least one cardiovascular risk factor
(i.e. smoking, hypertension, diabetes, hypercholesterolae-
mia, or a family history of CAD) were considered for study
inclusion if they had no history of prior MI or other vascular
disease, no anginal chest pain, and no other obvious disease.
Most study participants fulﬁlling these criteria were found
among totally asymptomatic subjects sent by their primary
care physician for life insurance or other check-up investi-
gations. The study protocol was approved by the insti-
tutional review boards of the four participating institutions.
Silent ischaemia detection
After documentation of a normal 12-lead ECG at rest,
bicycle ergometry was started at 50 W and increased by
25 W every 2 min until exhaustion. Asymptomatic ischaemia
was deﬁned as a 0.1 mV horizontal or downward sloping
ST-shift in more than one of the 12 ECG leads measured
80 ms after the J point without chest pain. Subjects present-
ing with this ﬁnding were asked to undergo stress imaging,
i.e. stress ECHO or stress MPS. These imaging tests were
performed according to standard techniques and ischaemia
was diagnosed only in the presence of unequivocally rever-
sible perfusion defects or new wall motion abnormalities,
respectively.
Randomization and interventions
Study participants with veriﬁed silent ischaemia consenting
to the study (written informed consent) were randomized
to intensive anti-ischaemic drug therapy and risk factor
control (MED group, n ¼ 26) or to risk factor control-only
(RFC group, n ¼ 28). MED group patients were given
anti-ischaemic drug therapy aiming to reduce or possibly
eliminate ischaemia on ergometry consisting of bisoprolol
5–10 mg/day, amlodipine 5–10 mg/day, molsidomine
4–12 mg bid, or combinations thereof. The order of starting
anti-ischaemic therapy and the increase of drug dosages or
switching to combination therapy were left to the discretion
of individuals’ primary care physician and follow-up investi-
gations according to the following rules: start with one
single drug, increase drug dosage after 1 month if ischaemia
persisted, combine with a second drug if ischaemia persisted
after 3 months, and so on. Decisions regarding the choice of
starting drug were left to the individuals’ primary care
physician but increases in drug dosage or a switch to combi-
nation therapy during follow-up was allowed only if symp-
toms occurred. In addition, MED group patients received
open-label acetosalicylic acid (100 mg/day). Risk factor
control,whichwasattempted inbothpatient groups, consisted
of counselling on eating habits, weight control, smoking cessa-
tion, and physical exercise with speciﬁc drug therapy allowed
for hypercholesterolaemia (statin), diabetes (oral anti-
diabetics, if necessary), or hypertension (an angiotensin-con-
verting enzyme inhibitor, if needed).
Follow-up and outcomes
All study participants were followed up after 3, 6, and
12 months and yearly thereafter for a pre-speciﬁed duration
of 10 years. Follow-up examinations included a clinical exam
as well as a bicycle ergometry and repeat rest/stress ECHO.
Pre-speciﬁed outcome events were assessed and included
the occurrence of angina pectoris (stable and unstable),
symptomatic and silent MI, death (from cardiac and non-
cardiac causes), and revascularization therapies (surgery
or angioplasty). MI was diagnosed in the presence
of typical chest pain, ST-segment elevation in the ECG,
and/or a typical rise and fall of cardiac enzymes according
to the deﬁnitions of the European Society of Cardiology.16
Silent MI was diagnosed in the presence of new Q-waves in
the resting ECG, new distinct wall motion abnormalities in
the resting ECHO, and a reduction in the left ventricular
ejection fraction of .5% (or of .10% without regional
wall motion abnormalities) between two subsequent ECHO
exams. Coronary angiograms were allowed only if symptoms
occurred. All outcome events were adjudicated by an inde-
pendent event committee blinded to the study group (W.K.
and M.Z.).
The primary endpoint was deﬁned as a combination of
cardiac death, non-fatal MI (symptomatic or silent), or
unstable angina pectoris leading to hospitalization or revas-
cularization (surgery or angioplasty). The secondary end-
point included the occurrence of chronic stable angina in
addition to outcome events of the primary endpoint. If
patients experienced more than one event of the primary
or secondary endpoint, only the ﬁrst event was counted. In
addition, the time course of physical performance and left
ventricular function, the appearance or disappearance of
objective signs of ischaemia, blood pressure control, as
well as drug adherence during follow-up were assessed as
further measures of outcome. In order to increase the
validity of these additional ﬁndings, patients who experi-
enced the primary endpoint were excluded in this analysis
at the time of the primary endpoint.
Statistical analysis
Software used for statistical analysis was STATA 8.2 (Stata-
Corp, College Station, TX, USA). Data are expressed as
percentages and mean+standard deviation. Continuous
variables were compared by the use of the Student t-test
assuming normal distributions or by the Wilcoxon rank sum
test for variables with non-normal distributions. Dichoto-
mous variables were compared by the x2 test or the Fisher
exact test when cell counts were less than ﬁve. Cox pro-
portional hazards models17 were used to calculate hazard
ratios and 95 percent conﬁdence intervals for the compari-
son of event rates in the MED and RFC groups without and
Swiss Interventional Study on Silent Ischaemia type I 2111
with adjustment for age, gender, and other assignments
which revealed possible inﬂuences on outcome in univari-
able analysis (including hypertension, diabetes, dyslipidae-
mia, and left anterior descending coronary artery
ischaemia). Deviations from the proportional hazards
assumption were tested by examining the global test of
the Schoenfeld residuals. The times to event were depicted
with the Kaplan–Meier estimates of the survival function. In
all tests, values of P  0.05 were considered signiﬁcant.
Analyses of the primary and secondary endpoints were
performed according to the intention-to-treat principle.
Results
Patient selection and characteristics
Figure 1 shows the patient screening, selection, and ran-
domization processes. Between 1992 and 1996, 522 subjects
with asymptomatic ST-segment depression during bicycle
ergometry, with at least one cardiovascular risk factor, and
without a history of vascular disease were identiﬁed. Of
them, 487 consented to a stress imaging test to verify
silent ischaemia. In 263 subjects, silent ischaemia was veri-
ﬁed by stress imaging for a positive predictive value of 54%
of the bicycle ergometry for this ﬁnding. A total of 224
subjects had to be excluded because ischaemia could not
be veriﬁed with imaging techniques (n ¼ 206) or a prior
silent MI was found at stress imaging (n ¼ 11) or angina
appeared during stress imaging (n ¼ 7). The 263 subjects
with veriﬁed silent ischaemia were asked to participate.
Only 54 subjects (21%) consented. The high percentage of
refusals was related to the possible need of drug therapy
and the frequent control examinations necessary for this
study in otherwise healthy asymptomatic subjects.
Baseline characteristics of study participants are shown
in Table 1. The age range was 41.8275.4 years without
any signiﬁcant differences between the two treatment
groups in risk factor prevalence, work load achieved,
severity of ST-segment depression during exercise, or
resting ejection fraction.
Adherence to treatment
Risk factor control resulted in similar discontinuation rates
for smoking in both patient groups during follow-up
(Table 2). Elevated cholesterol levels, hypertension, and
diabetes, if present, were treated in similar rates too;
however, body weight did not change signiﬁcantly during
the study period (Table 2). Drug treatment consisted
mainly in beta-blocking agents and/or calcium antagonists
Figure 1 Patient selection and ﬂow chart.
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and to a much lesser extent in long-acting nitrates
(Figure 2). According to protocol, these drugs were given
signiﬁcantly more often in MED compared with RFC patients
although the differences diminished over time, which, if
anything, would tend to underestimate the full effect of
MED therapy. This was also true for aspirin, which was
given in 100% of MED compared with 12% and up to 55% (at
1 and 10 years, respectively) of RFC patients.
Outcome events
Follow-up was completed after 10 years in all patients,
except in those patients who died and in one patient who
went to jail and was lost after 5.5 years. A summary of
outcome events is shown in Table 3. Cardiac death, non-fatal
MI as well as chronic angina, and revascularizations occurred
consistently less frequently in the MED group compared with
the RFC group. During a total of 483 person-years of obser-
vation, 20 patients had at least one outcome event of the
primary endpoint, of whom three were assigned to the MED
group and 17 to the RFC group (12 vs. 61%). This corresponds
to a hazard ratio of 0.12 (95% CI 0.03–0.43; P ¼ 0.001).
Figure 3 shows the event-free survival for the primary end-
point. The event rate per year for the primary endpoint was
1.1% in MED patients, signiﬁcantly lower than that in RFC
patients (8.0%); this difference translated into an absolute
risk reduction of 6.9% per year (95% CI 2.9–10.9; P, 0.001).
It is of note that 16 of the 17 primary endpoint events in the
RFC group were due to MI, of which ﬁve were silent. The
exclusion of silent MI from the endpoint deﬁnition still
resulted in a hazard ratio of 0.18 in favour of MED patients
(95% CI 0.05–0.66; P ¼ 0.01). If on the other hand chronic
stable angina was considered an additional event of the
endpoint deﬁnition in these initially asymptomatic patients
(secondary endpoint), the absolute risk reduction was even
larger: from 79 to 15% in RFC vs. MED patients for an absolute
risk reduction of 11.1% per year (95% CI 5.6–16.5%; P, 0.001).
There was no baseline variable, including age, gender, hyper-
tension, diabetes, dyslipidaemia, or ischaemia in the left
anterior descendent territory, which signiﬁcantly inﬂuenced
the treatment effect in Cox proportional hazard analysis.
Ischaemia, left ventricular function, and other
observations during follow-up
Data on ischaemia, left ventricular function, blood pressure,
and exercise performance in relation to treatment group
during follow-up are shown in Table 4. During follow-up,
patients of the MED group had signiﬁcantly lower rates of
exercise-induced ischaemia than patients of the RFC group.
At the 1 year follow-up, exercise-induced ST-segment
depression was signiﬁcantly lower in the MED group [1.0 mm
(SD 1.3 mm)] compared with the RFC group [1.8 mm (SD
0.5 mm); P ¼ 0.009]. The difference in exercise-induced
ischaemia between MED and RFC group gradually decreased
over time, maybe partly due to a certain increase in
anti-ischaemic drug use in the RFC group (Figure 2). In
addition, global left ventricular ejection fraction decreased
signiﬁcantly over time in patients of the RFC group (26.0%,
P ¼ 0.006), contrasting to a nearly constant ejection fraction
in the MED group (20.7%, P ¼ 0.597), resulting in signiﬁcantly
lower values at ﬁnal examination after 10 years. This is
remarkable since these data relate only to patients without
intercurrent infarction. Exercise performance and blood
pressure control were similar in both treatment groups
throughout follow-up except for a lower blood pressure in
the MED group at the 1 year follow-up. At the ﬁnal follow-up,
systolic/diastolic blood pressures at rest were (129+17)/
(80+11) mmHg in the MED group and (133+9)/(82+
7) mmHg in the RFC group (differences not signiﬁcant).
Discussion
SWISSI I is the ﬁrst prospective randomized study suggesting
a beneﬁcial effect of anti-ischaemic drug therapy and
aspirin in addition to standard risk factor control on
long-term outcome in otherwise healthy asymptomatic
Table 2 Risk factor control in MED and RFC patients
MED group
(n ¼ 26)
RFC group
(n ¼ 28)
Stopped smoking 8/14 (57) 10/17 (71)
High cholesterol treated 16/18 (89) 10/16 (63)
Hypertension treated 16/18 (90) 9/11 (82)
Diabetes treated 1/2 (50) 4/6 (67)
Weight change (0–10
years)
23.1 0.5
Numbers are number of patients treated/number of patients with risk
factor (percentages) or as indicated. P-values are not signiﬁcant between
groups for all comparisons.
Table 1 Baseline characteristics by treatment group
MED group
(n ¼ 26)
RFC group
(n ¼ 28)
P-value
Age, years 59.5+9.0 59.2+8.5 0.9
Female sex, n (%) 8 (31) 9 (32) 1
Blood pressure at rest,
mmHg
Systolic 140+17 143+19 0.55
Diastolic 85+8 86+11 0.57
Risk factors for CAD
Smoking, n (%) 12 (46) 15 (54) 0.93
Pack-years 18+21 17+18 0.85
Hypertension, n (%) 15 (58) 9 (32) 0.75
Dyslipidaemia, n (%) 13 (50) 12 (43) 0.33
Diabetes, n (%) 1 (4) 4 (14) 1
Family history of
CAD, n (%)
10 (38) 10 (36) 0.82
Two or more risk
factors, n (%)
17 (65) 16 (57) 0.54
Bicycle ergometry
Maximal workload, W 169+38 175+44 0.58
ST-segment
depression, mm
2.2+0.9 1.9+0.6 0.18
Ejection fraction, % 61.8+3.7 61.3+4.5 0.63
Ischaemic region
Anteroseptal, n (%) 9 (35) 9 (32) 0.7
Posterolateral, n (%) 6 (23) 9 (32) 1
Inferior, n (%) 11 (42) 11 (39) 0.48
Data are presented as mean+ standard deviation or as number of
patients (percentages).
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middle-aged subjects with silent exercise-induced ischae-
mia veriﬁed by stress imaging and at least one risk factor
of CAD. The low rate of otherwise healthy asymptomatic
patients agreeing to participate in such a pilot study docu-
ments the difﬁculty to perform a large-scale randomized
trial to this question and is an obvious reason for the lack
thereof. Selection of eligible patients for this study also
underscored the low positive predictive value (around 50%)
of the bicycle ergometry for the detection of ‘true’ silent
ischaemia in such a low disease-prevalent population. The
low disease prevalence is underscored by the excellent
10 year survival even of RFC patients with a mortality of
only 1.1%/year. Still, combined anti-ischaemic drug
therapy and aspirin not only reduced combined major
cardiac events during follow-up, but also resulted in a
persistently lower rate of exercise-induced ischaemia and
prevented a gradual decline of left ventricular function
noted in patients with risk factor control-only. Of note is
the relatively high rate of silent MI detected in these
patients with silent ischaemia as previously noted;18,19 but
even without these silent events, the difference in
outcome events remained signiﬁcant in favour of the MED
treatment strategy. These results were observed in the pre-
sence of a remarkable impact of risk factor control measures
in both treatment groups.
Table 3 Occurrence of outcome events according to treatment group
MED group
(n ¼ 26)
RFC group
(n ¼ 28)
Hazard ratio (95% CI) P-value
Unadjusted Adjusteda
Outcome eventsb
Cardiac death, n (%) 0 (0) 3 (10.7)
Non-fatal MIc, n (%) 1 (3.8) 16 (57.1) 0.05 (0.0120.35) 0.03 (0.0120.23) 0.001
Unstable angina, n (%) 2 (7.7) 0 (0)
Coronary artery bypass graft, n (%) 4 (15.4) 6 (21.4)
Percutaneous coronary intervention, n (%) 0 (0) 8 (28.6)
Stable angina not leading to revascularization,
n (%)
1 (3.8) 10 (35.7) 0.09 (0.0120.70) 0.09 (0.0120.71) 0.02
Death from non-cardiac causes, n (%) 0 (0) 1 (3.6)
Combined endpointsd
Cardiac death, non-fatal MIc, or unstable
angina, n (%)
3 (11.5) 17 (60.7) 0.14 (0.0420.49) 0.12 (0.0320.43) 0.001
Cardiac death, non-fatal MIc, or stable/unstable
angina, n (%)
4 (15.4) 22 (78.6) 0.13 (0.0420.37) 0.08 (0.0220.26) ,0.001
aAdjustment for age, gender, hypertension, diabetes, dyslipidaemia, and ischaemia in the anteroseptal region.
bMore than one type of outcome event (initial and subsequent events) allowed per patient.
cSymptomatic and silent MI.
dIf a patient experienced more than one outcome event of the endpoint, only the ﬁrst event was counted.
Figure 2 Drug therapy during follow-up.
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Previous studies in patients with silent ischaemia showed
the prognostic importance of this ﬁnding in patients with
additional angina,9,14 previous MI,10,11 coronary artery
bypass graft surgery,12 or angioplasty.13 The prognostic
importance of silent ischaemia type I documented by stress
MPS was also described in asymptomatic volunteers and
elderly subjects.9,20 The prevalence of and the association
between silent myocardial ischaemia and new coronary
events were found to be true for both older men and women
and both with and without cardiovascular disease.21,22 The
risk of coronary events in a 10 year follow-up of patients
with silent myocardial ischaemia was reported to depend on
the presence of cardiovascular risk factors,23 and it was
found that patients with silent ischaemia type I have a
better prognosis than patients with symptomatic stable
angina.24
There is, however, a debate as to whether silent ischaemia
type I should be treated since, in absence of symptoms, such
treatment can only be directed towards an improvement of
prognosis.25,26 The Asymptomatic Cardiac Ischemia Pilot
study and the Atenolol Silent Ischemia Study showed a beneﬁt
of either revascularization14 or drug therapy14,15 in patients
who had silent ischaemic episodes in addition to symptomatic
ones.1 SWISSI I is the ﬁrst study which attempted to extend
these ﬁndings to totally asymptomatic patients with silent
ischaemia type I, i.e. without any history of prior CAD disease.
Limitations
There are certain special aspects and limitations of the
present study. First, an unexpectedly low rate of subjects
consenting to study inclusion was observed, which makes
the estimates of effect size unstable. This low number of
patients was due to the inclusion of a low-risk CAD popu-
lation, mainly asymptomatic middle-aged men sent for life
insurance check-up examinations, which required veriﬁca-
tion of silent ischaemia by stress imaging. Furthermore,
these asymptomatic subjects had to be willing to participate
in a drug study with repeated examinations over a prolonged
period of time. Despite the small sample size, results
achieved statistical signiﬁcance because of a large effect
size. The impact of the small sample size was partially miti-
gated by the remarkably long length of follow-up achieved
(483 patient years). In addition, Cox proportional hazards
model showed similar results for adjusted and unadjusted
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Figure 3 Kaplan–Meier survival function of the primary endpoint (cardiac
death, non-fatal myocardial infarction, and unstable angina pectoris).
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analyses, suggesting the results were robust. This is sup-
ported by the fact that overall ﬁndings were not overly
dependent on one component of outcome. The open design
of the study treatment is another limitation, but it was
impossible to conduct such a long-term study with a
placebo control arm in these difﬁcult-to-motivate patients.
Thus, this study also does not show that a certain drug or
drug class is effective, but rather it provides a proof of prin-
ciple that anti-ischaemic drug therapy has beneﬁcial effects
on outcome in these patients. The difference between study
groups in aspirin use may have added to this effect although
aspirin is primarly known to improve survival and not to
reduce rates of ischaemic symptoms, objective signs of
ischaemia, nor to preserve left ventricular function, although
a reduced rate of episodes of ST-depression on Holter moni-
toring has been noted.27 Finally, the signiﬁcant treatment
effect found in SWISSI I parallels that recently found in
the medical treatment arm of the Clinical Outcomes Utilizing
Revascularization and Aggressive Drug Evaluation (COURAGE)
trial in stable coronary patients, although most of those
patients were mildly to moderately symptomatic.28
Conclusions
In conclusion, these data in asymptomatic subjects with
silent ischaemia but no history of CAD suggest that anti-
ischaemic drug therapy and aspirin may reduce subsequent
cardiac events, reduce ischaemia, and preserve left ventri-
cular function. The results of this study indicate that
asymptomatic subjects with exercise-induced ST-segment
depression at a check-up examination should have this
ﬁnding veriﬁed by stress imaging; if silent ischaemia can
be documented, physicians should consider prophylactic
anti-ischaemic drug therapy and aspirin in addition to
risk factor management. Further research is indicated to
conﬁrm these ﬁndings in a large population, identify the
effective intervention, isolate the population most likely
to beneﬁt from it, and clarify the underlying mechanisms.
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